Yang Shuangyin, Feng Yanmei, Yang Kuiliang, Pu Jie, Wang Pu
Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Respiratory Medicine, Chongqing Emergency Medical Center, Chongqing, China.
Int J Mycobacteriol. 2025 Apr 1;14(2):145-152. doi: 10.4103/ijmy.ijmy_33_25. Epub 2025 Jun 20.
Even with early antituberculosis (TB) treatment, some patients with pulmonary TB (PTB) may experience progression of chest computed tomography (CT) lesions. However, there is limited information on the causes and management of this progression during treatment. This study was undertaken to improve clinical understanding of the various causes and management strategies for the worsening of chest CT lesions in patients with PTB.
A retrospective analysis was performed on the medical records of 61 PTB patients. We evaluated the radiological features, clinical characteristics, laboratory findings, causes, and management of chest CT lesions progression in PTB during anti-TB treatment and compared the characteristics of patients in the paradoxical response (PR) group and the non-PR group.
The most common cause of the chest CT progression lesions was PR, accounting for 50.8% (n = 31) of the cases. Other important causes included insufficient anti-TB treatment (21.3%, n = 13), drug-resistant TB (8.2%, n = 5), and comorbidities such as bacterial infections (8.2%, n = 5), fungal infections (6.6%, n = 4), and lung cancer (4.9%, n = 3). Patients with PR were primarily treated by continuing their anti-TB management, whereas those with non-PR due to other causes received treatment targeting the underlying etiology. PR patients were younger (Mann-Whitney U-test, P < 0.001; 95% confidence interval [CI]: 15.8-32.2)., had more asymptomatic cases (74.2% vs. 4.0%; χ2 test, P < 0.001; odds ratio [OR]: 64.3, 95% CI: 12.5-330.2), showed higher Mycobacterium TB culture positivity (64.5% vs. 30.0%; χ2 test, P = 0.015; OR: 4.2, 95% CI: 1.4-12.6), and had quicker lesion progression than the non-PR group (P = 0.004; 95% CI: 1.0-3.0).
PR is the major cause of chest CT lesion progression in PTB during anti-TB. Continuation of anti-TB therapy can promote the absorption of lesions. Differences between PR and non-PR patients can help clinicians in diagnosing and guiding treatment strategies.
即使进行早期抗结核治疗,一些肺结核(PTB)患者的胸部计算机断层扫描(CT)病变仍可能进展。然而,关于治疗期间这种进展的原因和管理的信息有限。本研究旨在提高临床对PTB患者胸部CT病变恶化的各种原因及管理策略的认识。
对61例PTB患者的病历进行回顾性分析。我们评估了抗结核治疗期间PTB患者胸部CT病变进展的放射学特征、临床特征、实验室检查结果、原因及管理,并比较了矛盾反应(PR)组和非PR组患者的特征。
胸部CT进展性病变最常见的原因是PR,占病例的50.8%(n = 31)。其他重要原因包括抗结核治疗不足(21.3%,n = 13)、耐药结核病(8.2%,n = 5)以及合并症,如细菌感染(8.2%,n = 5)、真菌感染(6.6%,n = 4)和肺癌(4.9%,n = 3)。PR患者主要通过继续抗结核治疗进行处理,而因其他原因导致非PR的患者则接受针对潜在病因的治疗。PR患者更年轻(曼-惠特尼U检验,P < 0.001;95%置信区间[CI]:15.8 - 32.2),无症状病例更多(74.2%对4.0%;χ2检验,P < 0.001;比值比[OR]:64.3,95% CI:12.5 - 330.2),结核分枝杆菌培养阳性率更高(64.5%对30.0%;χ2检验,P = 0.015;OR:4.2,95% CI:1.4 - 12.6),且病变进展比非PR组更快(P = 0.004;95% CI:1.0 - 3.0)。
PR是抗结核治疗期间PTB患者胸部CT病变进展的主要原因。继续抗结核治疗可促进病变吸收。PR患者与非PR患者之间的差异有助于临床医生进行诊断和指导治疗策略。